3 results
Safety and performance will be based on a comparison of overall success rates of the Barricaid ARDand either a concurrent group (nonrandomized) of control patients treated by conventional surgicalmethods (e.g., noninstrumented discectomy) at select…
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
The primary objective is to determine if the addition of daratumumab to VRd will prolong PFS defined as the time from the date of randomization to the date of disease progression (assessed by International Myeloma Working Group [IMWG] criteria) or…